OPTOB
Opthea Limited
π¦πΊ ASX
π Overview
π Performance
π΅ Cost
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
N/A
Annual Growth
5 years average annual growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
1
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Opthea Limited - Option Expiring 30-Jun-2026
π Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π° Price*
$0.23
*Price may be up to 24 hours old
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in OPTOB
1
π Total Capital Earnings
N/A
π Average investment frequency
9 weeks
π΅ Average investment amount
$2,009
β° Last time a customer invested in OPTOB
141 days
OPTOB investor breakdown
π΅ Income of investors
More than 200k
50%
150k - 200k
100k - 150k
50k - 100k
Less than 50k
50%
πΆ Age of investors
18 - 25
26 - 34
35 - 90
100%
π Legal gender of investors
Female
Male
100%
Pearlers who invest in OPTOB also invest in...
ASIA.AX was created on 2018-09-18 by BetaShares. The fund's investment portfolio concentrates primarily on information technology equity. The investment objective of the BetaShares Asia Technology Tigers ETF is to provide an investment return that aims to track the performance of the Solactive Asia ex-Japan Technology & Internet Tigers Index (the Index), before taking into account fees and expenses.
π Performance (5Yr p.a)
9.00%
π Share price
$10.12 AUD
π HIGH PRICE GROWTH
π¦πΊ EX AUSTRALIA
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
14.66%
π Share price
$140.30 AUD
β³οΈ DIVERSIFIED
π HIGH PRICE GROWTH
π GLOBAL
π€ TECHNOLOGY
NDQ
NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.
π Performance (5Yr p.a)
28.52%
π Share price
$50.36 AUD
πΊπΈ UNITED STATES
π HIGH PRICE GROWTH
π€ TECHNOLOGY
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The firm has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
π Performance (5Yr p.a)
-15.29%
π Share price
$0.65 AUD
𧬠BIOTECHNOLOGY
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
4.27%
π Share price
$103.65 AUD
π¦πΊ AUSTRALIA
β³οΈ DIVERSIFIED
𧱠MATERIALS
πΈ FINANCIALS
Want more shares? Try these...
Orora Ltd. engages in the manufacturing and distribution of fiber, glass and aluminum beverage cans. The company is headquartered in Hawthorn, Victoria and currently employs 7,533 full-time employees. The company went IPO on 2013-12-18. The firm is focused on designing and delivering products and services that enable its customers' brands to thrive. Its operations span Australasia, North America, Europe and the United Arab Emirates. Its operations include Global Beverage and Orora Packaging Solutions (OPS). Its global beverage business includes glass manufacturing, glass decoration, closures manufacturing and cans manufacturing. Its OPS business is a vertically integrated provider of sustainable manufacturing, distribution and visual solutions across North America. The firm specializes in custom packaging design, automation, supply chain optimization and visual solutions for a broad range of sectors. Its products include glass bottles, aluminum cans, closures and caps, and boxes and cartons. Its services include printing and signage, product sourcing, and automation and engineering.
π Performance (5Yr p.a)
-7.97%
π Share price
$2.39 AUD
ποΈ SOCIALLY AWARE
π° HIGH DIVIDEND
π¦ LOGISTICS
Ordell Minerals Ltd is a AU-based company operating in Metals & Mining industry. The company is headquartered in Perth, Western Australia. The company went IPO on 2024-07-19. Ordell Minerals Limited is an Australia-based mineral exploration company. The firm has a prospective gold and lithium exploration portfolio, which includes three principal mineral assets: the Barimaia Joint Venture (JV) Project, the Goodia Project and the Fisher South Project located in the Yilgarn Craton of Western Australia (WA), Australia. The combined properties cover approximately 308 square kilometers (km2). The Barimaia JV Project comprises one mining lease, one exploration lease and 14 prospecting licenses in the Youanmi Terrane of the Yilgarn Craton near Mt Magnet. The Goodia Project is located within the eastern Goldfields region of WA and has the potential to host economic gold, nickel or lithium deposits. The project comprises one tenement E63/2313 and covers approximately 75km2. The Fisher South Project is located in the north-eastern Goldfields of WA, approximately 430km north of Kalgoorlie and comprises one tenement E53/2143, covering an area of 62 blocks (190km2).
π Share price
$0.32 AUD
βοΈ MINING
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The firm has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
π Performance (5Yr p.a)
-15.29%
π Share price
$0.65 AUD
𧬠BIOTECHNOLOGY